Frontline Pembrolizumab Regimens Receive Japanese Approval in Head and Neck Cancer

Japan’s Pharmaceuticals and Medical Devices Agency has granted approval to frontline pembrolizumab as monotherapy and in combination with chemotherapy for the treatment of patients with recurrent or distant metastatic head and neck cancer.

Read the full article here

Related Articles